New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 23, 2014
14:32 EDTPCYCPharmacyclics estimates raised ahead of Q2 report at Goldman
Goldman raised Pharmacyclics' Q2 Imbruvica US sales estimate to $93M from $82M, vs. consensus of $88M and 2014 to $409M from $383M based on IMS data. The firm rates shares a Buy with a $162 price target.
News For PCYC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 25, 2014
16:02 EDTPCYCPharmacyclics, Server agree to end pan-HDAC inhibitor collaboration
Pharmacyclics and Servier announced that they have mutually and amicably ended their collaboration pertaining to the ex-U.S. development of Pharmacyclics' pan-HDAC inhibitor compounds involving abexinostat, thereby returning global development and commercialization rights to Pharmacyclics. A provisional patent application for abexinostat tosylate was filed with the U.S. Patent and Trademark Office in 2013 and, if issued, would extend patent protection until 2034. Pharmacyclics will evaluate the full opportunity that the compound may afford, and plans to provide an update on this program in mid 2015.
September 16, 2014
07:03 EDTPCYCPharmacyclics VA contract worth $6 per share, says William Blair
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use